



Financial calendar 2020

Oslo, March 23, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the Company expects to make the following announcements during 2020:

Annual Report 2019

April 15, 2020

Business update (web-based conference) *

April 16, 2020

Annual General Meeting 2020 (web-based) *

April 22, 2020

Interim Report Q1 2020

May 12, 2020

Interim Report Q2 2020

August 27, 2020

Interim Report Q3 2020

November 17, 2020

*Web-based for safety reasons due to COVID-19. Further information to be published.

The above financial reports and any other news updates will upon their release be available at:

- the Company's website, www.vaccibody.com, where information relating to Vaccibody's Business update and Annual General Meeting 2020 will also be available in due course prior to the meeting.
- At NOTC's website, www.notc.no

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of head and neck. Vaccibody has a collaboration with Nektar Therapeutics, planning to start testing VB10.NEO in combination with bempedaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck in 2020. Vaccibody's front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced malignancies. The first-in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) has published positive 12 months data. Vaccibody has started a collaboration with Roche, exploring VB10.16 in combination with their checkpoint inhibitor atezolizumab (Tecentriq®) in up to 50 patients with advanced or recurrent cervical cancer. First patient is expected to be vaccinated in 2020. Further information about the company and its drug development programs and capabilities may be found online at <http://www.vaccibody.com>

Contact:

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

mengsig@vaccibody.com

Vaccibody AS

Oslo Research Park

Gaustadalléen 21

0349 Oslo, Norway